ZA200109639B - Control of wool growth in sheep and related animals. - Google Patents
Control of wool growth in sheep and related animals. Download PDFInfo
- Publication number
- ZA200109639B ZA200109639B ZA200109639A ZA200109639A ZA200109639B ZA 200109639 B ZA200109639 B ZA 200109639B ZA 200109639 A ZA200109639 A ZA 200109639A ZA 200109639 A ZA200109639 A ZA 200109639A ZA 200109639 B ZA200109639 B ZA 200109639B
- Authority
- ZA
- South Africa
- Prior art keywords
- skin
- use according
- composition
- wool
- treated
- Prior art date
Links
- 210000002268 wool Anatomy 0.000 title claims description 43
- 241001494479 Pecora Species 0.000 title claims description 36
- 241001465754 Metazoa Species 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 claims description 45
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical group NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 41
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 40
- 238000002679 ablation Methods 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 17
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 17
- 230000005670 electromagnetic radiation Effects 0.000 claims description 14
- 230000001678 irradiating effect Effects 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000010008 shearing Methods 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 2
- 241001416177 Vicugna pacos Species 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229930002875 chlorophyll Natural products 0.000 claims description 2
- 235000019804 chlorophyll Nutrition 0.000 claims description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 2
- 229960005233 cineole Drugs 0.000 claims description 2
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 claims description 2
- 230000035617 depilation Effects 0.000 claims description 2
- 150000004033 porphyrin derivatives Chemical class 0.000 claims description 2
- 230000003244 pro-oxidative effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- HPINPCFOKNNWNW-UHFFFAOYSA-N thiete Chemical compound C1SC=C1 HPINPCFOKNNWNW-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 40
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 13
- 241000920471 Lucilia caesar Species 0.000 description 13
- 229950003776 protoporphyrin Drugs 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 241001331845 Equus asinus x caballus Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000002479 balanitis Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000283903 Ovis aries Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 231100000760 phototoxic Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 230000002165 photosensitisation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ATBNMWWDBWBAHM-UHFFFAOYSA-N n-decyl-n-methyldecan-1-amine Chemical compound CCCCCCCCCCN(C)CCCCCCCCCC ATBNMWWDBWBAHM-UHFFFAOYSA-N 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- -1 tungsten halogen Chemical class 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/203—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser applying laser energy to the outside of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/00476—Hair follicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
’
A
1
CONTROL OF WOOL GROWTH IN SHEEP AND RELATED ANIMALS
This invention relates to a method and composition for permanently reducing or preventing wool growth at a selected locality or localities in sheep and related animals. In a particular application of the invention, the breech and/or pizzle area of sheep are treated in order to prevent the incidence of blow-fly strike and/or balanitis.
Blow-fly strike and balanitis (pizzle rot) are significant problems for sheep and wool growers. It is estimated that in Australia alone, losses exceeding $150 million per annum are caused by blow-fly strike and its containment.
Current methods for containing blow-fly strike and balanitis include crutching (i.e. periodic close shearing around the breech and hind legs), ringing of the pizzle and the widely practised treatment known as the Mules operation. The Mules operation or "mulesing" involves the removal of a large flap of skin from lambs below the tail and down the hind leg using shears and without anaesthetic. While providing effective life-long protection : against blow-fly strike, the operation causes considerable trauma to the recipient animals and can be associated with long-term arthritic problems and is likely to be phased out or banned for these reasons. The scarring caused by the Mules operation may also reduce the sale price of the carcass and hide. Consequently, considerable research has been directed to the identification of non-surgical mulesing methods.
In Proc. Aust. Soc. Animal Prod. 11, 189-192 (1976) Pratt and Hopkins ’ disclosed the use of a number of cryogenic, irritant, fixative and protein denaturizing agents. Of these, the protein denaturizing agents were the only . compounds found to be successful and included 40% phenol and a mixture of 20% phenol and 50% orthocresol. Application was by painting 15-30ml onto the relevant area. In discussing the effectiveness of these agents, the authors noted a number of disadvantages arising from the toxic and irritant properties of phenol and cresol, such as the need to take special precautions to prevent injury to human operators and increased toxicity to lambs resulting from excess absorption through intact skin.
In Wool Technology and Sheep Breeding 23 (2) 26-27 (1976) the same authors reported the successful use of a 40% phenol emulsion which was applied to the relevant areas in an amount of 10-20ml using a roll-on dispenser. In this paper it is stated that the phenol rapidly penetrates the superficial layers of the skin, destroying cells and paralyzing nerve endings to produce an almost painless effect, whilst the germicidal nature of the phenol prevented infection in the healing tissue. Again it is noted that operators need to observe rigorous safety precautions.
Australian patent specification No. 73793/91 describes a non-surgical mulesing method involving the application of a cationic compound such as a halogenated quaternary ammonium compound (e.g. didecylmethylamine ammonium chloride), which complexes with glycosaminoglycans present in the skin to form full skin thickness eschars which are ultimately sloughed to leave linear scars similar to those resulting from the Mules operation. While found to be effective in reducing blow-fly strike incidence, the method has not been widely practised because it appears to cause sheep a similar amount of pain to that of surgical mulesing. A further disadvantage is the risk of injury to operators.
Accordingly, there remains a need for an effective, non-surgical mulesing method which is safe in use and causes little or no trauma to the recipient animals. It is also desired that such a method avoids damage to the skin which might devalue the hide.
The present invention provides, in one aspect, a method for the controlled ablation of wool follicles within skin of a wool bearing animal at : one or nore selected localities, comprising; treating said skin at said selected locality(ies) with a composition comprising at least one follicle-ablating agent and, subsequently, irradiating said skin at said selected locality(ies) with electromagnetic radiation of an intensity and/or wavelength to bring about the photodynamic ablation of at least a portion of the wool follicles present in the skin at said selected locality(ies).
The invention is hereinafter described in reference to the preferred trealment of the wool follicles of sheep, although the present invention is suitable for treatinent of the wool follicles of other wool bearing animals such as goats and alpacas.
In a preferred form, the present invention provides a method for the controlled ablation of wool follicles within skin of sheep at one or more selected localities, comprising; treating said skin at said selected locality(ies) with a composition comprising at least ons follicle-ablating zgert and subsezuentic irradiating said skin at said selected localitviies’ with electromagnetic radiation of an intensity and wavelength to bring about the photodynamic ablation of at least a portion of the wool follicles present in the skin at said selected locality(ies).
The follicle-ablating agent(s) may be selected from photosensitisers and substances which induce the formation and/or accumulation of an endogenous photosensitiser(s). Suitable photosensitisers include porphyrin derivatives and analogues (e.g. haematoporphyrin (HpD) derivatives such as di-haematoporphyrin ether). It is, however, preferred to use a substance which induces the formation and/or accumulation of an endogenous photosensitiser(s).
Most preferably, the method comprises treating the skin at said selected locality(ies) by applying 5-aminolevulinic acid (5-ALA) or a derivative (e.g. esterified 5-ALA or 5-ALA conjugated to one or more fatty acids may show enhanced skin permeability) or analogue thereof. While not wishing to be bound by theory, it is believed that 5-ALA, which is readily absorbed by the skin, induces the biosvnthesis in skin of an excess of ’ protoporphyrin IX (PpIX). Accumulated PpIX, when irradiated with electromagnetic radiation of a photosensitising wavelength (e.g. white light . or broad-spectrum red light), causes phototoxic damage or death (i.e. ablation) of skin cells including cells of wool follicles.
The composition is preferably applied topically or intradermally/subcutaneously (e.g. by hydraulic or pneumatic applicators).
The composition preferably comprises a suitable carrier. For topical application, the carrier is preferably selected from diethylene glycol monoethyl ether (DGME) and mixtures including propylene glycol and glycerol. Other suitable carriers include ethanol and isopropyl myristate.
The composition may further comprise one or more chelating agents (e.g. EDTA and 2,2-dipyridyl) and/or other agent(s) (e.g. chlorophyll and prooxidants) to augment the effect of the follicle-ablating agents.
Prior to application of the composition, the wool at the skin locality(ies) to be treated may be removed, wholly or in part. Methods for removing the wool include shearing, close clipping with shears (e.g. to a residual height of 1-2 mm), defleecing with epidermal growth factor (EGF), shaving and depilation. Degreasing of the wool and skin at the locality(ies) to be treated with soap or an alcohol wash is also advisable.
Following treatment of the skin with the composition, it is preferred that a period of time (e.g. within 24 hours) sufficient to allow for the substantial completion of absorption and metabolism of the follicle-ablating agent be allowed to pass before being irradiated with electromagnetic radiation of an intensity and/or wavelength to bring about the photodynamic ablation of wool follicles. Presently, it is believed that the irradiation should : be conducted between 2 and 15 hours, more preferably between 3 and 10 hours, after treating the skin with the said composition.
Irradiation may be conducted using any suitable source of electromagnetic radiation. The electromagnetic radiation will be of an intensity and wavelength to bring about the photodynamic ablation of at least a portion of the wool follicles by sensitising the absorbed follicle-ablating agent and/or accumulated exogenous photosensitiser(s). The irradiation may be conducted using a monochromatic or polychromatic light source.
Preferably, the irradiation is conducted using a source of light of wavelength 600 to 700 nm at a dose (i.e. intensity) of 100-175 (preferably, 150) J/cm” and a fluence rate of less than 150 mW/cm?, however, other sources of light may . be used including ambient sunlight.
By varying the composition, the method provides for the controlled ablation of a selected percentage of follicles within the selected locality(ies).
Preferably, the method results in the ablation of at least 50%, more preferably at least 70%, of the follicles within the selected locality(ies). For use with sheep, it may be preferred that the method results in the ablation of about 70- 85% of the wool follicles in the selected locality(ies). The subsequent regrowth provided by the 15-30% viable (i.e. non-ablated or regenerated)
follicles is insufficient for the occurrence of blow-fly strike and provides an advantage in that it prevents the development of skin cancers which might otherwise occur if 100% of the follicles were ablated. The development of skin cancers, however, is not anticipated to be a problem with treatment of 5 the breech and/or pizzle area of sheep since these areas are substantially shaded from the sun by the sheep's body. 100% ablation of wool follicles in sheep skin may be achieved with a composition comprising 10-20% (w/w) 5-ALA in a suitable carrier at pH 2.5 (unbuffered) or 4.0. Decreasing the amount of 5-ALA tc 5-9% is expected to iz recuce the percentages of azlated Iolliciss t= T0-85%.
Varying the duration and/or {tensity of the irradiation used is alsc expected to affect the percentage of ablated follicles. For example, with a composition comprising 10% (w/w) 5-ALA in a suitable carrier at pH 2.5 (unbuffered), an irradiation time of about 5 minutes (with white light at an intensity of 150J/cm?®) may be expected to achieve 100% ablation whereas an irradiation time of about 3 minutes may be expected to achieve 70-85% ablation.
In a further aspect, the present invention provides a method for non- surgical mulesing of a sheep, the method comprising; treating the skin at the breech area of the sheep with a composition comprising at least one follicle-ablating agent and, subsequently, irradiating at least a portion of the treated area with electromagnetic radiation of an intensity and/or wavelength to bring about photodynamic ablation of at least a portion of said wool follicles in said treated skin.
While the invention offers an alternative to the Mules Operation, it may also be employed for pizzle ringing.
Accordingly, in vet a further aspect, the present invention provides a method for non-surgical pizzle ringing of a sheep, the method comprising; treating skin at or near the pizzle area of the sheep with a composition . comprising at least one follicle-ablating agent and, subsequently, irradiating at least a portion of the treated area with electromagnetic radiation of an intensity and/or wavelength to bring about photodynamic ablation of at least a portion of said wool follicles in said treated skin.
Moreover, the application of the method of the invention is not limited to the containment of incidence of blow-fly strike and balanitis. That is, the method may also be used for "wigging", removal or reduction of wool from areas around the face, "crutching” (to prevent blow-fly strike and dags) and branding of sheep or other wool bearing animals.
The method of the present invention may also be used in conjunction with other wool treatments. For example, the method may be used as an adjunct to biological defleecing (e.g. EGF defleecing).
The terms "comprise", "comprises" and "comprising" as used throughout the specification are intended to refer to the inclusion of a stated step, component or feature or group of steps, components or features with or without the inclusion of a further step, component or feature or group of steps, components or features.
The invention will hereinafter be further described by way of reference to the following, non-limiting examples and accompanying figure.
Brief descriplion of the accompanying figures:
Figure 1 provides graphical results discussed in Example 2 hereinafter.
The figure shows that in skin samples taken from three sheep, the concentration of PpIX, a metabolite of 5-ALA thought to cause phototoxic damage or death to skin cells upon irradiation with electromagnetic radiation of a photosensilising wavelength, peaked between about 6 and 13 hours after application of 5-ALA. The results suggest that the optimal time for irradiation is between about 8 and 10 hours after application of 5-ALA, however some other, empirical evidence from treated sheep indicates that these tines are effective but that optimal levels in the follicles may be attained prior to this (e.g. between about 3 and 4 hours).
Example 1: Ablation of wool follicles in sheep : Preparation of active agent: 5-aminolevulinic acid (8-aminolevulinic acid; 5-amino-4-oxopentanoic i acid) (5-ALA) is combined with any suitable vehicle for topical application and absorption. Tests on sheep employed a mixture of 20% (w/w) propylene glycol plus 80% (w/w) commercial sorbolene cream containing 10% glycerine (glycerol). 5-ALA was tested at 5% (w/w) and 17% (w/w).
Preparation of skin surface for treatment:
Skin was prepared for treatment by using a defleecing dose of epidermal growth factor, by shaving or by using a depilating agent such as
‘ thioglycollate. The area was swabbed with 70% ethanol to degrease it and assist penetration of the cream.
Photodvnamic treatment: 5-ALA mixture was rubbed into the area briefly by hand and the animals then left for a period of 3 hours to allow the 5-ALA to be absorbed and metabolised in the skin and follicles. After 3 hours the treatment area was irradiated with a white light source (e.g. a modified slide projector) containing a heat filter. Light, 600 - 700nm, was administered at a dose of 125]/ci’ at a fluence rate of less than 150 mW/cm®. In the case of the slide iz projector fcoriaining 2 200W bulb? the lens was hel 10 z= Zo “he sic for no more than 10 mins. Spray anaesthetic was sometimes =nzlied after ths light was removed.
Results:
Following treatment there is some slight localised edema which persists for about 48 hows. There is some discolouration then crusting of the skin in the treated area. After 4-5 weeks the skin regains its normal appearance but wool regrowth is either sparse or non-existent in the treated area. Tests with mixtures containing 5% (w/w) and 17% (w/w) 5-ALA were found to be effective. The treatment appears to be relatively painless with no side effects or chemical residues in the animal.
Example 2: 5-ALA metabolism time profiles in sheep skin samples
Tests were conducted to determine the period of time, following application of 5-ALA, required to achieve peak concentrations of the 5-ALA metabolite PpIX in skin. Since this metabolite is believed to cause phototoxic damage or death to skin cells upon irradiation with eléctromagnelic radiation of a photosensitising wavelength, it was reasoned that more consistent ablation of wool follicles in sheep could be achieved by irradiating the 5-ALA treated skin at a time when the peak concentration of . ao PpIX was expected.
Test method: 5-ALA was formulated as a 10% (w/w) aqueous solution in 90% (w/w)
DGME in the presence of various test compounds to measure their effectiveness in enhancing PpIX formation. These formulations were applied to clipped, mid-flank skin of several sheep after swabbing with 70% ethanol.
Skin biopsies were commenced immediately thereafter using a sterile 0.8cm human biopsy punch. Samples were taken at 2 hourly intervals for times up to about 20 hours. Skin samples were immediately frozen in dry ice and stored at 70°C until processed. Skin samples were then thawed, hoinogenised in aqueous buffer and PpIX extracted into an acid solution and then into an organic phase of ethyl acetate. PpIX levels were measured in a spectrofluorimeter using a set of standards of known PpIX concentration.
The excitation wavelength was 430nm and emission was measured at 595nm.
Results:
The results of the tests are shown in Figure 1. The formulations used for the treatment of the three sheep were:
Animal 4347 --- 10% 5-ALA, 90% DGME
Animal 4365 --- 10% 5-ALA, 90% DGME, 10mM EDTA : Animal 4468 --- 109% 5-ALA, 90% DGME, 20mM 2,2-dipyridyl.
The profiles of PpIX formation shown in Figure 1 suggest that the optimal treatment time (for irradiation with electromagnetic radiation) would be about 8 to 10 hours after 5-ALA application. A similar conclusion has been made from PpIX formation profiles obtained using other 5-ALA formulations (data not shown).
Discussion:
Since obtaining the PpIX formation profiles shown in Figure 1, follicle -ablation experiments have been conducted on a further 8 sheep using the formulation: 10% 5-ALA, 90% DGME, 10mM EDTA (applied to close-clipped breech), followed 10 to 14 hours later with a 5 minute irradiation. The light source used for the irradiation was a bank of five 24V - 250W tungsten halogen projector lamps at a distance to yield a dose of about 150J/cm (heat, and any excess UV, was shielded with a glass panel treated with an infra-red ) reflective coating).
Initial observations indicated that the treated animals showed a more . consistent level of follicle ablation. Subsequent observations (up to 2 years after treatment) have generally indicated that animals which are bare in the treated area 2 months after. treatment, remain so permanently.
Example 3: Blow-fly strike prevention field trial
In October 1999, a field trial was conducted in Armidale, NSW,
Australia, to assess the effectiveness of the method of the present invention in preventing blow-fly strike in sheep.
Field triul method: 191 Merino lambs (4-5 month old ewes and whethers) were divided into three groups of 66, 66 and 59 animals per group, with the latter group serving as an untreated (i.e. control) group. 66 animals were subjected to conventional, surgical mulesing and the remaining 66 animals were treated with the method of the present invention, specifically application of a 5-
ALA formulation (10% (w/w) 5-ALA in 80% (w/w) DGME, 5% (w/w) cineole, 200 mM 2,2-dipyridyl) to the breech area. Prior preparation of the breech consisted of close-clipping (i.e. so that 1-2 mm of wool remained) and pin swabbing briefiv with 7095 e*hano! “inimals were “her -reated with a © minute exposure to a 1000 watt meta! hzingsn light ‘zstimateZ dosz 220
J'cm”® at a fluence raie of 150 mW, cm”) 10 hours after application of ths 5-
ALA formulation. All animals were left to graze at pasture and were observed closely during the following seasons which were favourable for blow-fly strike.
Results:
Breech-strike results as of 9 May 2000 (a period of 7 months) were as shown in Table 1.
TABLE 1: with breech-strike *including 5 multiple or repeat strikes.
Discussion: ’
The results demonstrate that the method of the present invention is effective in significantly reducing the incidence of breech-strike as compared to untreated sheep.
While not wishing to be bound by theory, it is believed that the success of the method of the present invention may, in part, also stem from an effect on skin structure, vasculature and other organs associated with the wool follicles in the treated area. Thus, the ablation of sebaceous glands and
. \ skin microvasculature may affect both the ability of wool follicles to regenerate as well as lhe likelihood of the skin becoming inflamed and damaged in wet conditions that normally predispose to, or attract, blow-fly strike.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (29)
- _" Claims: oo . 1. The use of at least one follicle-ablating agent in a method of making a medicament composition for use in a method for the controlled ablation of wool Co follicles within skin of a wool bearing animal at one or more selected localities, the method comprising; treating said skin at said selected locality(ies) with said composition and, subsequently, : irradiating said skin at said selected said locality(ies) with electromagnetic radiation of an intensity and/or wavelength to bring about the photodynamic ablation of at least a portion of the wool follicles in the skin at said selected locality(ies).
- 2. The use according to claim 1, wherein the said wool bearing animal is a goat, alpaca or sheep.
- 3. The use of at least one follicle-ablating agent in a method of making a medicament composition for use in a method for non-surgical mulesing of a sheep, the method comprising; treating the skin at the breech area of the sheep with said composition : and, subsequently, : irradiating at least a portion of the treated skin with electromagnetic : radiation of an intensity and/or wavelength to bring about photodynamic ablation of at least a portion of said wool follicles in said treated skin.
- 4. The use of at least one follicle-ablating agent in a method of making a medicament composition for use in a method for non-surgical pizzle ringing of a sheep, the method comprising; treating skin at or near the pizzle area of the sheep with said composition and, subsequently, irradiating at least a portion of the treated skin with electromagnetic radiation of an intensity and/or wavelength to bring about photodynamic ablation of at least a portion of said wool follicles in said treated skin. AMENDED SHEET 2002 -ft- 20
- 12 oo . 5. The use of at least one follicle-ablating agent in a method of makinga medicament composition for use in a method for crutching a sheep, the method
- ’ . comprising; treating skin in an area of the breech and hind legs of the sheep with said ' composition and, subsequently, oo ) irradiating at least a portion of the treated skin with electromagnetic : : ~ radiation of an intensity and/or wavelength to bring about photodynamic ablation of at least a portion of said wool follicles in said treated skin. Eo 6. The use according to any one of the preceding claims, wherein the : follicle-ablating agent(s) is a photosensitiser.
- 7. The use according to claim 6, wherein the photosensitiser is selected 135 froin porphyrin derivatives and analogues.
- 8. The use according to claim 6, wherein the photosensitiser is selected from 5-aminolevulinic acid (5-ALA).
- 9. The use according to claim 6, wherein the photosensitiser is 5- aminolevulinic (5-ALA) conjugated to one or more fatty acids.
- 10. The use according to claim 6, wherein the photosensitiser is Co esterified 5-aminolevulinic (5-ALA) conjugated to one or nore fatty acids. oo
- 11. The use according to any one of the preceding claims, wherein the a composition is applied topically to said skin. .
- 12. The use according to claim 11, wherein the composition includes a carrier selected from diethylene glycol monoe thy! ether (DGME) and mixtures including propylene glycol and glycerol. oo
- 13. The use according to any one of the preceding claims, wherein said : composition further comprises one or more chelating agents. ]
- 14. The use according to any one of the preceding claims, wherein said : composition further comprises chlorophyll or prooxidants. AMENDED SHEET 2002 -1+- 20 yoo WO 00/71089 | PCT/AU00/00487.
- 15. The use according to any one of the preceding claims, wherein the : skin to be treated is pre-treated to wholly or partially remove wool fibres: -” .
- 16. The use according to claim 15, wherein the skin to be treated is pre- treated by a method selected from shearing, close clipping with shears, defleecing with epidermal growth factor (EGF), shaving and depilation.
- 17. The use according to any one of the preceding claims, wherein said : step of irradiating is conducted between 2 and 15 hours after treating said skin with the composition. :
- 18. The use according to claim 17, wherein said step of irradiating is conducted between 3 and 10 hours after treating said skin with the composition. :
- 15 . : 19. The use according to claim 17, wherein said step of irradiating is So conducted about 10 hours after treating the skin with the composition.
- 20. The use according to any one of the preceding claims, wherein said said electromagnetic radiation is provided by a source of light of wavelength 600 to 700 mm. : oo
- 21. The use according to claim 18 or 19, wherein said electromagnetic radiation has an intensity of 100-175 J/cm? and a fluence rate of less than 150 oo mW/cm?. :
- 22 The use according to any one of the preceding claims, wherein the method results in the ablation of at least 50% of the wool follicles in the treated skin. : 30 :
- 23. The use according to any one of the preceding claims, wherein the method resulls in the ablation of at least 70% of the wool follicles in the : treated skin.
- 24. The use according to any one of the preceding claims, wherein the : method results in the ablation of 70-85% of the wool follicles in the treated skin.
- 25. The use according to any one of the preceding claims, wherein the method results in the ablation of substantially all of the wool follicles within ~ the treated skin. ENDED THIET 2002 -w- 9g .
- 26. A composition comprising 10% (w/w) of an aqueous solution of 5- aminolevulinic acid (5-ALA) and 90% (w/w) diethylene glycol monoethyl ether (DGME).
- 27. A composition comprising 10% (w/w) of an aqueous solution of 5- aminolevulinic acid (5-ALA), 90% (w/w) diethylene glycol monoethyl ether (DGME) and 10 mM EDTA.
- 28. A composition comprising 10% (w/w) of an aqueous solution of 5- aminolevulinic acid (5-ALA), 90% (w/w) diethylene glycol monoethyl ether (DGME) and 20 mM 2,2-dipyridyl.
- 29. A composition comprising 10% (w/w) of an aqueous solution of 5- aminolevulinic acid (5-ALA), 80% (w/w) diethylene glycol monoethyl ether (DGME), 5% (w/w) cineole and 200 mM 2,2-dipyridyl.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ0444A AUPQ044499A0 (en) | 1999-05-19 | 1999-05-19 | Control of wool growth |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200109639B true ZA200109639B (en) | 2002-11-22 |
Family
ID=3814647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200109639A ZA200109639B (en) | 1999-05-19 | 2001-11-22 | Control of wool growth in sheep and related animals. |
Country Status (5)
Country | Link |
---|---|
AU (1) | AUPQ044499A0 (en) |
GB (1) | GB2368015B (en) |
NZ (1) | NZ515655A (en) |
WO (1) | WO2000071089A1 (en) |
ZA (1) | ZA200109639B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4754731B2 (en) * | 2001-07-31 | 2011-08-24 | コスモ石油株式会社 | Pig growth promoter and method for promoting pig growth |
EP1312353A1 (en) | 2001-11-16 | 2003-05-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for hair removal |
AUPR971001A0 (en) * | 2001-12-21 | 2002-01-24 | Bio-Clip Pty Ltd | Compositions |
NZ552862A (en) | 2005-03-15 | 2009-03-31 | Animal Ethics Pty Ltd | A topical analgesic composition |
GB0700580D0 (en) | 2007-01-11 | 2007-02-21 | Photocure Asa | Use |
CN107233303A (en) * | 2017-08-07 | 2017-10-10 | 苏州纳美特生物科技有限公司 | A kind of aminolevulinic acid cold cream and its preparation method and application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63249577A (en) * | 1987-04-06 | 1988-10-17 | 浜理薬品工業株式会社 | Permanent hair removing method, preparation and device |
US5871480A (en) * | 1991-10-29 | 1999-02-16 | Thermolase Corporation | Hair removal using photosensitizer and laser |
US5669916A (en) * | 1994-09-28 | 1997-09-23 | The General Hospital Corporation | Method of hair removal |
US6143287A (en) * | 1996-02-27 | 2000-11-07 | New York Blood Center, Inc. | Method and composition for hair removal |
FR2762504B1 (en) * | 1997-04-29 | 1999-09-10 | Cird Galderma | HAIR REMOVAL PROCESS |
DE19832221C2 (en) * | 1998-07-17 | 2000-07-27 | Manfred Neubauer | Method and device for cosmetic hair removal |
-
1999
- 1999-05-19 AU AUPQ0444A patent/AUPQ044499A0/en not_active Abandoned
-
2000
- 2000-05-19 GB GB0129486A patent/GB2368015B/en not_active Expired - Fee Related
- 2000-05-19 WO PCT/AU2000/000487 patent/WO2000071089A1/en active IP Right Grant
- 2000-05-19 NZ NZ515655A patent/NZ515655A/en not_active IP Right Cessation
-
2001
- 2001-11-22 ZA ZA200109639A patent/ZA200109639B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NZ515655A (en) | 2004-11-26 |
GB0129486D0 (en) | 2002-01-30 |
WO2000071089A1 (en) | 2000-11-30 |
GB2368015A (en) | 2002-04-24 |
GB2368015B (en) | 2004-11-03 |
AUPQ044499A0 (en) | 1999-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9814906B2 (en) | Method and apparatus for skin treatment | |
Marmur et al. | A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer | |
US9227082B2 (en) | Method and apparatus for acne treatment using low intensity light therapy | |
EP1443964B1 (en) | Photodynamic therapy for the treatment of hair loss | |
AU2002326716A1 (en) | Method and apparatus for acne treatment | |
EP3082788B1 (en) | Pulse photodynamic treatment of acne | |
CA2247611C (en) | Method and composition for hair removal | |
JP2007522137A (en) | Photodynamic therapy to treat acne | |
US20090131499A1 (en) | Photodynamic therapy for skin related problems | |
CA2568744A1 (en) | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins | |
Fien et al. | Photodynamic therapy for non-melanoma skin cancer | |
WO2008052350A1 (en) | Photodynamic therapy for the treatment of hidradenitis suppurativa | |
ZA200109639B (en) | Control of wool growth in sheep and related animals. | |
JP2010047590A (en) | Method and apparatus for acne treatment | |
Rothwell et al. | Research into alternatives to mulesing | |
AU777772B2 (en) | Control of wool growth in sheep and related animals | |
JP2004518715A (en) | Relaxation of soft fibrous soft tip | |
US20050148567A1 (en) | Treatment of tattoos by photodynamic therapy | |
CA2884306C (en) | A method for the permanent removal of hair | |
Ma et al. | Effect of photodynamic therapy using 5-aminolevulinic acid on 4-nitroquinoline-1-oxide-induced premalignant and malignant lesions of mouse tongue | |
JP2001172154A (en) | Peeling composition | |
Sidoroff | Topical sensitization—oncologic indications—actinic keratoses | |
Wieman et al. | Microvascular effects of photodynamic therapy | |
RU2260462C1 (en) | Method for treating keloid cicatrices by applying photodynamic therapy techniques |